Dan Lichtman became Biomodels’ Managing Partner in 2012. Following sales and marketing positions at Abbott, J+J and Bayer, Mr. Lichtman recognized the opportunities presented by advances in medical technology and founded an in-vitro diagnostic instrumentation company at a time when diagnostics was in its infancy and its distribution was an unsophisticated part of hospital supply. Additionally, Mr. Lichtman saw drug discovery as synergistic with diagnostics and founded a contract research organization. The success of both companies reflects Mr. Lichtman’s commitment to innovation and excellence. He brings his management skills as a CEO and his commitment to translational research to Biomodels to amplify the corporate philosophy of an employee centric culture.

Dr. Sonis is senior academic at Harvard, Brigham and Women’s Hospital and the Dana-Farber Cancer Institute and a world-renowned expert in epithelial injury associated with cancer therapy. His development of predictive animal models has enabled the investigation of the biological basis of cancer regimen-related epithelial injury and has catalyzed the development of potential therapies. Dr. Sonis’ interest in the genomic basis for toxicity risk and its pathology has led to innovative genomics-based analytical approaches to clinically actionable outcomes to personalize disease therapy. Steve is the former President of Triad, an international not-for-profit company which focused on the adverse health and economic outcomes of cancer treatment toxicities and serves as a special government employee of the FDA. He has published extensively on the clinical, biological, and health economic aspects of cancer and complications associated with its treatment. Steve holds several patents and is the author of more than 275 original publications, reviews, and chapters and is completing his eleventh book. He obtained degrees from Tufts and Harvard and completed his post-doctoral education (tumor immunology) at Oxford University where he was a Knox Fellow.

As Chief Operating Officer, Dr. Lyng is responsible for the oversight of all of Biomodels’ preclinical research programs, day-to-day management of company operations, and strategic growth of the research/business portfolio. Additionally, Greg works closely with Biomodels’ clients to ensure proper study design and utilization of the most appropriate and clinically relevant models of disease in which to test potential therapeutics. Greg’s scientific expertise lies in the areas of inflammatory disease, cancer supportive care, and diseases of the central nervous system. Since joining Biomodels in 2007, and prior to his role as COO, Greg served in varying capacities, from Scientist to Director of Research. He has been instrumental in the expansion of the business through building client relationships as well as increasing the number and

clinical translatability of the disease models offered by Biomodels. Dr. Lyng received his Ph.D. in Biomedical Sciences from the University at Albany School of Public Health and his B.S. in Neuroscience from St. Lawrence University.

Cathy Trewin joined Biomodels in 2012 as its Chief Financial Officer bringing with her extensive experience with pre-clinical research and medical diagnostic instrumentation companies including Inter-Medico, NoAb BioDiscoveries, and LabOne. In addition, she has held public accounting and other industry positions at KPMG, Ernst Young and Avery Dennison. Ms. Trewin holds a Bachelor of Commerce degree from the University of Toronto and is a member of Canadian Institute of Chartered Accounts and holds a CPA, CA designation.

Dr. Parello joined Biomodels in 2016 as an Associate Scientist after completing her post-doctoral studies in the Department of Pathology at the University of Massachusetts Medical School where she focused on the development of a clinically relevant, humanized murine model of Experimental Autoimmune Encephalomyelitis (EAE) as a conduit for assessing interventions for multiple sclerosis (MS). Caitlin received her PhD from Boston University School of Medicine in 2014, where she adapted two murine models of Shiga Toxin 2- induced kidney injury, and was an NIH- funded pre-doctoral fellow and Russek award winner. At Biomodels, Caitlin has successfully combined her background in adaptive immunity and murine model development, and has incorporated both into assisting clients in addressing questions around product development in areas which include the interaction of the microbiome and immune system, the potential dysbiosis mediating inflammatory/autoimmune disorders, and determining if restoration of eubiosis can be therapeutic for such disorders. Dr. Parello led the establishment of our germ-free/gnotobiotic murine isolator facility, and serves as the lead scientist on microbiome-related studies.

Dr. Borkowski joined Biomodels in 2017 as an Associate Scientist after completing his postdoctoral studies in the department of Immunology and Microbial Science at The Scripps Research Institute. His postdoctoral work focused on elucidating novel mechanisms of wound healing based on the recognition of lipid antigens in the skin. Andrew received his Ph.D. in Biomedical Sciences from the University of California, San Diego in 2014, where he discovered a role for toll-like receptor 3 in skin permeability barrier repair. Dr. Borkowski has diverse interests in the field of immunology, including host-microbe interactions, the influence of the microbiome on human health, and the dynamics of physical and immunological barrier

surfaces. Andrew’s Biomodels’ portfolio focuses on projects associated with innate and adaptive immunity at barrier sites, and interventions targeting inflammatory and autoimmune disorders.

Dr. Smith joined Biomodels in 2017 as an Associate Scientist after completing her postdoctoral work at Massachusetts General Hospital (Harvard Medical School) where her work focused on understanding the relationship between checkpoint inhibitor expression patterns and the functional capabilities of tumor-infiltrating lymphocytes in the context of head and neck squamous-cell carcinoma. Nicole received her Ph.D. from Boston University School of Medicine in 2016, where she developed a novel murine model that enabled the study of heterotypic adaptive immune memory responses following lung infections with Streptococcus Pneumoniae. In addition, using this model, she identified a novel lung localization pattern for antigen-specific tissue-resident memory Th17 cells. Nicole’s expertise in model development, and her diverse background and expertise in the fields of adaptive immunity and mucosal and cancer immunology have made her an immediate contributor to expanding scope of models and clinical indications.

Dr. McKayla Nicol joined Biomodels in 2022 as a Scientist I after completing a dual title PhD program in Pathobiology and Clinical and Translational Sciences at the Pennsylvania State University. McKayla’s graduate research as an NIH-funded pre-doctoral fellow focused on understanding the disease pathogenicity of multiple high-impact respiratory pathogens and developing novel methods to safeguard against known bioweapons. This work involved both in vivo and in vitro studies at BSL2 and BSL3 levels. McKayla also earned two bachelor’s degrees from the Pennsylvania State University in Biomedical Engineering and Mechanical Engineering. She has worked across a variety of interdisciplinary projects and has experience in infectious diseases, microbiology, immunology, engineering, multi-omics, and more. At Biomodels, McKayla is using her diverse background to develop and execute studies in several areas of focus. She is also leading the expansion of oncology centered models and capabilities for the company.

Ashlee Graham serves as Biomodels’ Business Development and Contracts Manager. Since joining Biomodels in 2010 Ashlee has immersed herself in all aspects of the business. Ashlee has been an instrumental part of developing processes and polices for human resources, purchasing, and operations. Over the last three years Ashlee's primary focus has shifted to business development, client contracting (Confidentiality and Master Research Agreements) and marketing. Ashlee is responsible for developing, facilitating and maintaining relationships with clients – our major priority - as a point of contact from initial inquiry through project completion.

Samantha Rogers joined Biomodels in 2011 as a Research Technician and through a great commitment to our research programs is now our Animal Research Facility Manager. Samantha utilizes her breadth of experience in in vivo research to support the scientific team and ensure that our clients’ projects are performed with technical rigor. Sam is also responsible for laboratory scheduling, facility oversight, regulatory compliance and serves as a vendor liaison. Samantha graduated from Mt. Ida College with her BS in Veterinary Technology.

Brett Van Dam serves as Biomodels Lab Supervisor and IACUC Chair. Since joining Biomodels in 2013, Brett has utilized his training in animal health/welfare, as well as his technical expertise, to develop and lead a wide variety of translational disease models. In addition to his role as IACUC chair, Brett supervises the day-to-day in-vivo operations and serves as an animal research specialist to provide additional support and training to our technical team. Brett graduated with a BS in Animal Technology from Mount Ida College.